ABSTRACT
Case Scenario
A 36-year-old woman of Sicilian descent with a family history of type 2 diabetes presented to her primary care physician with a history of obesity and hypertension. Her clinical examination findings were unremarkable. She had a fasting glucose concentration of 124 mg/dL (7.0 mmol/L; fasting plasma glucose cutoff, ≥126 mg/dL [7. 0 mmol/L]) that was observed during her last physician's office visit. Her blood pressure was 140/80 mm Hg. She admitted to feeling tired and getting up at night occasionally to urinate. A hemoglobin (Hb) A 1c test was ordered on two separate occasions. The HbA 1c method used in the laboratory was immunoassay, and both results were reported as normal at 5.3% and 5.1% (cutoffs: prediabetes, 5.7%-6.4%; diabetes, ≥6.5% ). 1 The patient was notified of the results and Upon completion of this activity you will be able to:
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reassured that she did not have diabetes but was advised to visit her physician again in 3 months for follow-up. On relocating to a different state for employment reasons, the patient presented to her new primary care physician approximately 4 months later for a workplace physical examination. At this visit, her fasting glucose concentration was found to be 142 mg/dL (7.8 mmol/L). Results of a follow-up, 75-g, 2-hour oral glucose tolerance test were consistent with a diagnosis of diabetes: 2-hour glucose of 220 mg/dL (12.2 mmol/L; 2-hour plasma glucose cutoff ≥200 mg/dL [11.1 mmol/L]). 1 An HbA 1c test was ordered and performed in a laboratory using ion-exchange high-performance liquid chromatography (HPLC), and results returned with an abnormally high HbA 1c value of 16.7%, remarkably different from the patient's previous HbA 1c test result. Based on the shape of the HPLC chromatogram, a comment was appended to the HbA 1c result indicating that a presumptive Hb variant was suspected. Subsequent laboratory testing and investigation by the patient's physician revealed the presence of hemoglobin S (HbS) reduced β (β + )-thalassemia in this 36-year-old woman.
Background
Hb is composed of four globin chains. HbA 0 , the most abundant nonglycated form of adult Hb, consists of two α and two β chains (α 2 β 2 ) and accounts for approximately 95% to 98% of Hb. Other normal Hbs present in adults include HbF (α 2 γ 2 ) and HbA 2 (α 2 δ 2 ), each making up approximately 2% of total Hb. In the presence of glucose, HbA 0 is glycated to form HbA 1a1 (addition of fructose-1,6-diphosphate to the amino terminus of the HbA β chain), HbA 1a2 (addition of glucose-6-phosphate to the amino terminus of the HbA β chain), HbA 1b (addition of a pyruvate to the amino terminus of the HbA β chain), or HbA 1c (nonenzymatic addition of glucose to the amino-terminal valine residues of the HbA β chains). HbA 1c accounts for more than 80% of HbA 1 and is formed in two basic steps: glucose binds reversibly to Hb as an aldimine or Schiff base, which in turn undergoes an Amadori rearrangement to form a stable, irreversible ketoamine. HbA 1c forms in humans at a slow rate as a posttranslational modification throughout the lifespan of the RBC. 2 Several studies have established a direct relationship between HbA 1c and average blood glucose concentrations. [3] [4] [5] The onset and progression of diabetic complications can be delayed by maintaining near-normal HbA 1c levels. 3, 4 Because HbA 1c reflects the average blood glucose concentration over the previous 2 to 3 months (normal RBC lifespan), it is currently the most widely used index of average glycemia for the routine monitoring and prevention of long-term complications of diabetes. In addition to its use in monitoring diabetic patients, the American Diabetes Association (ADA) and the World Health Organization (WHO) have endorsed the use of HbA 1c for the diagnosis of diabetes and recommend that only NGSP (previously referred to as the National Glycohemoglobin Standardization Program)-certified HbA 1c methods performed in clinical laboratories be used for diagnosis.
When using HbA 1c for diagnosing and/or managing the care of diabetic patients, it is crucial to be aware of the factors known to interfere with the HbA 1c test. These interferences may arise through analytic means as well as through biologic variables affecting clinical interpretation. This report focuses on HbA 1c interferences resulting from the presence of Hb variants.
Common Hemoglobinopathies

Hb Variants
Hb variants arise from mutations and/or deletions in the genes encoding for the α and β chains that result in amino acid changes. Of the hundreds of Hb variants that have been identified to date, the four most common worldwide are HbS, hemoglobin E (HbE), hemoglobin C (HbC), and hemoglobin D (HbD), in descending order of prevalence. Each of these Hb variants, depending on the method used, may cause an inaccurate HbA 1c result because of analytic interference 6 or, alternatively, an HbA 1c value that is clinically misleading because of biologic variables affecting the interpretation of the result. 7 If the prevalence of conditions that alter the RBC lifespan is high in a patient population, it may be beneficial to use an HbA 1c assay that can presumptively identify these conditions to prevent reporting inaccurate HbA 1c values in these cases. 7 
Hemoglobin S
HbS is produced when a valine is substituted for a glutamic acid at position 6 in the β chain. Persons carrying a single copy (heterozygous) of the mutated gene are described as having sickle cell trait (HbAS); those with two defective copies (homozygous) of the gene have sickle cell disease (HbSS). It has been estimated that 2.5 million people in the United States and 300 million people worldwide have sickle cell trait. In the United States, approximately 90,000 to 100,000 individuals are affected by sickle cell disease. 8 Sickle cell disease is characterized by the formation of long, inflexible chains of Hb that can facilitate RBCs to become caught in small capillaries, causing significant amounts of organ damage. In addition, HbSS is often associated with anemia because of a decrease in the RBC lifespan. In patients with sickle cell disease, the RBC lifespan is significantly shortened (~10-20 days for HbSS vs ~120 days for HbAA). 9 However, in patients with sickle cell trait, the RBC lifespan is approximately 93 days, which is currently considered to be normal. 10 
Hemoglobin C
The HbC allele can be found in up to 50% of individuals in West Africa. Migration has seen the spread of this Hb variant to many other regions of the world, and it is carried by approximately 3% of African Americans. This Hb variant arises when the glutamic acid found at position 6 of the HbA β chain is replaced by lysine. Carriers of a single allele of the HbC variant are reported to enjoy complete health, whereas those with HbC disease commonly present with mild hemolytic anemia. The RBC lifespan in patients with the HbC allele is approximately 87 days. 11 
Hemoglobin E
The HbE variant arises from a mutation in the HbA β chain that results in the substitution of a glutamic acid for lysine at position 26. This mutation also results in reduced synthesis of the β chain of HbE through the activation of a cryptic messenger RNA splice site, producing a thalassemiclike phenotype. The HbE allele is common in Southeast Asia, and it can be found in some areas at a frequency equal to that of HbA. Approximately 30% of Southeast Asians living in the United States are carriers of the HbE variant. Although HbE trait is clinically asymptomatic, the effect of this variant on the RBC lifespan has not been investigated. 11 
Hemoglobin D
HbD is found in approximately 2% of North Indians and descendants from Pakistan and Afghanistan living in the United States. This variant is produced when the glutamic acid at position 121 on the HbA β chain is changed to a glutamine. Several HbD variants have been identified, with the most common known as HbD-Punjab/Los Angeles. Persons heterozygous for HbD are clinically asymptomatic. The RBC lifespan of HbD trait has been reported in the literature as 115 days. 11
β-Thalassemia
The WHO estimates that approximately 1% to 5% of the world's population are carriers of β-thalassemia. 12 Point mutations, small deletions, or small insertions may result in absent (β 0 ) or β + β-globin synthesis. Unlike HbS, which produces a mutated form of β-globin, β-thalassemia affects actual production of the β-globin chain. As a consequence, the production of δ-globin and γ-globins may be increased, resulting in higher levels of HbA 2 and fetal Hb (HbF). The clinical manifestations of these mutations can range from asymptomatic (β-thalassemia minor) to completely transfusion dependent (β-thalassemia major). 13 In the more severe forms of thalassemia, the loss of balance between α-and β-globin synthesis results in a toxic aggregation of unpaired α chains early in RBC development, therefore leading to a shortened RBC lifespan. 14 Patients with HbS β-thalassemia have one HbS gene and either a β + or β 0 gene. The clinical manifestation of the disease may be either in the form of severe sickle cell disease (HbS β 0 -thalassemia) or a milder form of sickle cell disease (HbS β + -thalassemia). Asymptomatic children and adults have been reported to carry a specific β-thalassemia allele. 15 Similar to HbSS, the lifespan of the HbS β-thalassemia RBC is shortened.
In 2009, there were approximately 38.9 million nonHispanic African Americans with HbS β-thalassemia living in the United States. 16 Of these, around 8% carry the HbS allele. When combined with an estimated prevalence rate of 5% for β-thalassemia, 17 it is estimated that approximately 156,000 non-Hispanic African Americans are affected by HbS β-thalassemia. The presence of HbS β-thalassemia is known to result in falsely elevated HbA 1c measurements because of analytic interferences using certain methods, 18 as seen in the case presented herein.
HbA 1c Methods and Interference From Hb Variants
Analytic interferences have been investigated for the majority of the common, commercially available HbA 1c methods in the presence of heterozygous HbS, HbC, HbE, and HbD [19] [20] [21] [22] [23] [24] and are summarized at www.ngsp.org (accessed June 16, 2013) . HbA 1c can be measured in clinical laboratories by means of immunoturbidimetric assay (immunoassay), enzymatic assay, boronate affinity, ion-exchange HPLC, or capillary electrophoresis (CE). A list of currently approved Food and Drug Administration assays, reagents, and kits is shown in ❚Table 1❚. 25 Reporting of analytically inaccurate results most often can be avoided if the user carefully follows the manufacturer's instructions. 26 However, some methods and/or manufacturers' instructions alone do not provide sufficient information for making the correct decision about reporting analytically accurate or clinically useful results. Some vendors of HbA 1c methods have multiple, different HbA 1c assays commercially available (see Table 1 ), each potentially having its own unique analytic interference issues. It is important that each laboratory understands the analytic advantages and challenges associated not only with the general HbA 1c method but also with the specific assay they operate. 
Immunoassay
Enzymatic Assay
For enzymatic methods, whole blood samples are lysed and subjected to extensive proteolytic digestion. This process releases amino acids, specifically the glycated N-terminal valine from the Hb β chains. The signal produced by the glycated valines in a subsequent chromagenic reaction is used to calculate HbA 1c ❚Figure 2❚. These methods are unaffected analytically by the presence of Hb variants. However, like the highly specific second-and third-generation immunoassay HbA 1c methods, the end user is unable to discern the presumptive presence of homozygous Hb variants in patient samples.
Boronate Affinity Chromatography
Boronate affinity is a structurally specific method that recognizes the cis-diol groups of glucose bound to Hb. 26 It tends to demonstrate the least analytical interference from the presence of heterozygous Hb variants. 60 Although it is an advantage to identify the presence of some of these Hb products, it is important to note that different ion-exchange HPLC methods for HbA 1c measurement, even from the same vendor, have different chromatographic resolving power. The advantage of being able to measure HbA 1c using ion-exchange methods that do not use highresolution chromatography (with longer runtimes) is the shorter time required for sample analysis. The challenge with decreased chromatographic resolution, however, is the increased risk of interference from the Schiff base, carbamylated Hb, or Hb variants, which may coelute with the peaks of interest and cause an erroneous HbA 1c result. There is an advantage to being able to visualize an analytic interference that exists in patient samples (eg, whereby these Hb derivatives cannot be separated from HbA or HbA 1c ) so that inaccurate HbA 1c results will not be reported. However, some ion-exchange HPLC assays are analytically inaccurate because of interference from common Hb variants. 6
Capillary Electrophoresis
CE separates Hb molecules on the basis of charge and hydrodynamic volume ❚Figure 5❚. 61 Charged molecules are highly resolved by their electrophoretic mobility. Separation depends on electrolyte pH and electro-osmotic flow. As with some other forms of highly sophisticated models of chromatography, various Hb products, as well as other Hb byproducts or Hb variants, can be presumptively identified using CE. Studies have demonstrated that none of the most common heterozygous Hb variants (HbS, HbC, HbD, and HbE) analytically interfere with HbA 1c quantification using CE. ❚Figure 5❚ Capillary electrophoresis (CE) for hemoglobin (Hb) A 1c measurement. CE separates Hb species based on their electrophoretic mobility, defined by both their charge and hydrodynamic size (ie, mass). A high-voltage power supply is used to generate an electric field that facilitates the migration of molecules through the capillary tube from the anode to cathode. Positively charged Hb species in patient RBC lysate will be detected first, in decreasing order of their charge-to-mass ratios. For example, two molecules with the same positive charge will be further resolved by size, with the larger of the two molecules moving the fastest. These are followed by neutral species and finally by negatively charged Hb species. A representative electrophoretogram (not drawn to scale) shows the separation of HbA 1c from HbA 0 .
Clinical laboratories should be aware of the limitations of their HbA 1c assays, which may preclude the clinical usefulness of HbA 1c results, particularly in geographic locations with populations who are likely to have a high prevalence of Hb variants or conditions that would affect the RBC lifespan. Laboratories serving patient populations with a high prevalence of Hb variants may choose to (1) implement electronic hospital information system algorithms to assist the physician in automatically choosing an appropriate method for determining HbA 1c based on medical history 7 or (2) implement laboratory processes to identify analytic interferences in such populations. 63 such cases, it is possible for the HbA 1c test result to be clinically misinterpreted. For example, in patients with conditions that shorten the RBC lifespan, as in the case patient's HbS β + -thalassemia, the reported HbA 1c value is likely to be low de novo. Reporting results in these cases has the potential to give a false impression of average glycemia over approximately the preceding 120 days when in fact it is representing average glycemia over a more shortened RBC lifespan.
Alternative methods of assessing average glycemia (eg, glycated albumin and/or fructosamine) are recommended in these populations. Unfortunately, these measurements are not yet nearly as standardized as HbA 1c . No guidelines or goals are established on glycated protein values in these populations that can be followed by clinicians or diabetic patients. Importantly, clinicians should be cautious when using glycated albumin and fructosamine as an estimate of long-term average blood glucose. First, glycated albumin and fructosamine assess the degree of glycemia over a period of approximately 2 to 3 weeks, as opposed to 2 to 3 months for HbA 1c . Second, glycated albumin and fructosamine have not been correlated with the development of long-term complications resulting from diabetes mellitus, as was shown with HbA 1c.
2
It is currently accepted that the most common Hb variant traits (eg, HbAS, HbAC, HbAE, and HbAD) do not alter the RBC lifespan to a level that would interfere with the clinical interpretation of HbA 1c . It is therefore recommended by the ADA that HbA 1c values be used in patients who harbor Hb variant traits as long as the assay used is not analytically affected by the presence of that Hb variant. 1 
Case Summary
HbA 1c is the most widely used marker of average glycemia and is now also a recommended criterion for diagnosing diabetes. In situations in which HbA 1c measurements do not correlate with clinical impression and/or blood glucose values, as in the case presented here, the presence of an interference, such as an Hb variant, should be considered. Using an HbA 1c assay that is unaffected analytically by the presence of common Hb variants is important. One might also consider using an alternative method that is capable of presumptively identifying the presence of common Hb variants. The laboratory performing the HbA 1c test has the discretion to comment on both the specific method or assay used for analysis as well as the presumptively identified Hb variant observed. Providing comments to clinicians about the limitations of the HbA 1c assay used in their patient population (specifically in regard to analytic interference or biologic variables that affect HbA 1c levels) can assist in HbA 1c interpretation. Some examples of comments that accompany HbA 1c results from different laboratories have been previously described. 62 
